RxCelerate Sponsors Rising Tennis Star Joanna Garland
CAMBRIDGE, England, July 4, 2018 (Newswire.com) - RxCelerate, the world-leading out-sourced drug development platform announced today a sponsorship deal with 16 yr old Joanna Garland, a leading player on the international junior tennis circuit. The Stevenage, UK, based player reached the Quarter Finals of the girls singles competition at the French Open at Roland Garros in June.
“We are excited to have the opportunity to support the development of a young sportswoman, who exhibits the same mix of talent and determination that has made the RxCelerate team so successful,” said Dr Jill Reckless, Chief Executive Officer at RxCelerate.
Joanna, who was the most successful British-based player in the junior singles at the French Open, begins her challenge in the girls singles tournament at Wimbledon this week.
“It is hugely challenging for young tennis players”, said Hamid Hejazi, who coaches Joanna. “The support RxCelerate is providing will make a real difference.”
Although this is the first time RxCelerate has sponsored an athlete, the company regularly supports local charities. “The success of a company like RxCelerate depends on our people. Giving something back to the communities in which we operate is therefore very important to us” said David Grainger, Executive Chairman at RxCelerate. “We are tremendously excited to watch Joanna develop and grow into a world-leading tennis player.”
About RxCelerate
RxCelerate is an out-sourced drug discovery and development company, founded in Cambridge UK in 2012, with a focus on working smarter. It has grown rapidly to become one of the leading providers of drug development services. RxCelerate operates a unique model, providing capabilities to discover and develop drugs for clients, designing as well as executing every aspect of the research and development plan.
RxCelerate offers a wide range of services. The biology team specializes in vivo pharmacology, offering proprietary models of a wide range of human diseases, as well as complex cell-based assays. The chemistry team provides medicinal chemistry, including in silico screening, and synthesis that integrates seamlessly with the in vitro testing capability. A dedicated team designs the optimum discovery or development strategy for each project, as well as integrated program management. By working closely together, these teams can deliver pharma-grade drug product candidates at a fraction of the cost of traditional approaches.
For more information, please visit us at rxcelerate.com and connect with us on Twitter (@RxCelerate).
Contact our UK headquarters: jill@rxcelerate.com Tel: +44 (0)1223 804240.
Contact our US headquarters: laura@rxcelerate.com Tel: +1 (857) 409-6028
Source: RxCelerate